RxDoctor Payments Data

Fernando Taveras, MD

Psychiatry · New York, NYNPI 1194769067

Payments from drug & device makers

$20,756in general payments, 2019–2025

Across 857 payments — averaging $24.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$5K
  • AbbVie$3K
  • Otsuka America Pharmaceutical, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Neurocrine Biosciences, Inc.$2K
  • Vanda Pharmaceuticals Inc.$2K
  • plus $6K from 25 others

What the payments were for

  • Food & beverage$20,50399%
  • Education$2521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,756 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$16,193
Medicare patients
49
Services billed
177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole205$374,941
IngrezzaValbenazine Tosylate20$174,443
VivitrolNaltrexone Microspheres111$170,582
VraylarCariprazine Hcl79$139,648
Invega SustennaPaliperidone Palmitate49$124,596
Abilify MaintenaAripiprazole51$113,716
TrintellixVortioxetine Hydrobromide81$61,193
Lurasidone Hcl97$55,080
FanaptIloperidone12$50,883
AmbienZolpidem Tartrate45$27,077
EquetroCarbamazepine35$14,212
Effexor XrVenlafaxine Hcl18$13,259
Quetiapine Fumarate1,157$10,960
Aripiprazole478$10,208
Trazodone Hcl1,060$10,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$2,002$488,657256 claims
Neurocrine Biosciences, Inc.Ingrezza$1,844$174,44320 claims
Alkermes, Inc.Vivitrol$4,809$170,582111 claims
AbbVieVraylar, Namzaric, Fetzima$2,566$154,510107 claims
Johnson & JohnsonInvega Sustenna$332$124,59649 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$378$61,19381 claims
Vanda Pharmaceuticals Inc.Fanapt$1,803$50,88312 claims
Validus Pharmaceuticals LLCEquetro$35$14,21235 claims
Almatica Pharma LLCSertraline Hcl$73$4,141661 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →